Discussion in regards 2 presentations:
Safety data – GNRH Analogues, focus on CVD risk profile by Dr. Alan So – CUA
– PCa therapy induced CVD toxicity
– ADT plus newer antiandrogens
– Radiotherapy alone or in combination
– Data from latest trials – HERO
Safety data – mHSPC therapy and CVD risk profile by Prof. Axel Merseburger – EAU
– Data from animal models & basic research
– Other treatment modalities (chemotherapy, surgery, ADT alone or in combination)
– New treatment modalities and CVD toxicity
Live webinar contains:
Case study (incl Cardiac biomarkers) by Ass. Prof. Katie Zhang – ICOS
Q&A by panellists Dr. Alan So & Prof. Axel Merseburger